AXL and urinary bladder carcinoma: Binding sites for the FOS and JUN components of AP1 are present in the AXL promoter and functional studies have confirmed their involvement in the regulation of AXL expression in chronic myeloid leukemia (CML) and bladder cancer, respectively [15, 16].